IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).
IgM myeloma is a very rare and poorly defined entity. In a detailed assessment of 10 cases, it was demonstrated that 70% had an aberrant phenotype based on the expression of CD19, CD45, CD27 and Cyclin D1 but all cases lacked CD56 and CD117. Interphase fluorescence in situ hybridization demonstrated deletion 13 in 50% while 5/8 cases assessed had a t(11;14). Despite the high incidence of the t(11;14), CD20 was only expressed in one of nine cases. We conclude that IgM myeloma is a distinctive subset characterized by a CD20-CD56-CD117- phenotype and the t(11;14).
Feyler
Sylvia
S
Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. sylviafeyler@doctors.org.uk
O'Connor
Sheila J M
SJ
Rawstron
Andy C
AC
Subash
Chezhian
C
Ross
Fiona M
FM
Pratt
Guy
G
Drayson
Mark T
MT
Ashcroft
John
J
Cook
Gordon
G
Owen
Roger G
RG
D000368:Aged; D000369:Aged, 80 and over; D018951:Antigens, CD20 / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis*; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D012189:Retrospective Studies; D014178:Translocation, Genetic
D018951:Antigens, CD20; D019002:CD56 Antigen; D007075:Immunoglobulin M; D019009:Proto-Oncogene Proteins c-kit